Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody(R) ADG126 (muzastotug) in Combination with KEYTRUDA(R) (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC).
In: GlobeNewswire, 2024-02-09
Zeitungsartikel
Zugriff:
Titel: |
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody(R) ADG126 (muzastotug) in Combination with KEYTRUDA(R) (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC).
|
---|---|
Zeitschrift: | GlobeNewswire, 2024-02-09 |
Veröffentlichung: | 2024 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|